Ignite Creation Date:
2025-12-24 @ 9:46 PM
Ignite Modification Date:
2026-01-02 @ 6:50 AM
Study NCT ID:
NCT07070232
Status:
RECRUITING
Last Update Posted:
2025-11-19
First Post:
2025-07-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Sponsor:
BioNTech SE
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumor | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Combination with other investigational agents | View |
| None | Programmed death-ligand 1 (PD-L1) | View |
| None | Antibody-drug conjugate (ADC) | View |
| None | Human epidermal growth factor receptor 3 (HER3) | View |
| None | Programmed Death-1 (PD-1) | View |
| None | Programmed Death-1 monoclonal antibodies | View |
| None | Combination chemotherapy | View |
| None | Anti vascular endothelial growth factor-A (anti-VEGF-A) | View |
| None | Bispecific antibody | View |
| None | Immunotherapy | View |
| None | Dose optimization | View |
| None | Time to progression | View |
| None | Vascular endothelial growth factor (VEGF) | View |
| None | Cutaneous Melanoma | View |
| None | Rare melanoma | View |
| None | Actionable oncogenic alterations (AGA)-negative non-small cell lung cancer (NSCLC) | View |
| None | Epithelial growth factor receptor mutated (EGFRm) NSCLC | View |